Kissei Pharmaceutical And Wakamoto Pharmaceutical Co-Promote Salagen
This article was originally published in PharmAsia News
Executive Summary
Kissei Pharmaceutical and Wakamoto Pharmaecutical signed an agreement May 2 to co-promote Kissei's Salagen (pilocarpine), a drug used to treat dryness of the mouth and throat that may occur after radiation treatment for cancer of the head and neck, and to patients with Sjogren's syndrome. Kissei obtained the drug's exclusive development and marketing right in Japan from MGI Pharma, a subsidiary of Eisai. According to the agreement, Kissei and Wakamoto will promote the drug to assigned medical facilities, but Kissei will continue to solely handle manufacturing, marketing and distribution. (Click here for more - Japanese language